Natera, Inc. shares fall 1.96% intraday after RBC raises price target to $268.

Natera, Inc. declined 1.96% in intraday trading. The company's stock price decrease may be attributed to the news that RBC has raised its price target on Natera to $268 from $255, which could indicate a potential overvaluation of the stock. Additionally, the investigation by Pomerantz Law Firm into claims on behalf of investors of NeoGenomics, Inc. may have caused concern among investors in the diagnostics sector, leading to a sell-off in Natera's stock.